Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Neurology Clerkship > Multiple Sclerosis and Other Myelopathies > Flashcards

Multiple Sclerosis and Other Myelopathies Flashcards

1
Q

Natalizumab

A

Anti-α4 integrin subunit. Prevents T cell recruitment to regional lymph nodes.

Progressive multifocal leukoencephalopathy is a common consequence of use. PML is an opportunistic CNS viral infection caused by the John Cunningham Virus. The risk of developing PML with natalizumab treatment is related to three factors:

  1. Whether the patient has antibodies to the JC virus
  2. Whether the patient has received prior immunosuppressive therapy
  3. Length of treatment with natalizumab beyond 2 years

anti-JC antibody screening required. In patients who are not found to have JC virus antibodies, the risk of developing PML is exceedingly low. Given these risks, JC virus antibody–negative patients on natalizumab therapy must be screened for JC virus antibody every 6 months to evaluate for seroconversion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Fingolimod

A

S1P receptor agonist. Oral therapy for MS.

Downregulates S1P receptor within the lymphatic system, preventing T cells from following the chemotactic gradient and egressing. In effect, fingolimod decreases the cycle frequency of T cells and increases the lymphatic T cell storage at any given moment.

Bradycardia and macular edema are sometimes seen. Baseline electrocardiogram (ECG) and cardiac monitoring are required with the first dose. Baseline ophthalmologic examination and subsequent periodic ophthalmologic monitoring are also necessary.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

John Cunningham virus

A

One of the two major polyomaviruses.

Causes progressive multifocal leukoencephalopathy. In this disease, patients develop CNS white matter damage. May cause memory loss, poor speech, and impaired coordination.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Uthoff’s phenomenon

A

Recurrence or emergence of neurologic symptoms with heat (due to environmental temperature in the summer, hot bath, or exercise).

This occurs with any demyelinating disease/myelitis. This is why MS tends to flare in the early summer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

L’hermitte’s sign

A

Electrical sensation down the spine with forward flexion of the neck.

This can occur in any type of cervical myelopathy and is not specific to MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Internuclear ophthalmoplegia

A

Due to disruption of the medial longitudinal fasciculus (MLF)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Afferent pupillary defect

A

Due to prior optic neuritis.

An afferent pupillary defect may be present even in patients who have not had a clear clinical episode of optic neuritis

When you swing the light, if both pathways are intact, pupillary size should not change. If one pathway is relatively defective, both pupils will dilate when the ipsilatreal eye is illuminated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Neuroimaging of MS

A
  • Key diagnostic test for MS is MRI
  • Classic radiologic features of MS are small, ovoid T2/FLAIR hyperintensities that are perpendicularly oriented to the lateral ventricles and corpus callosum.
  • Acute lesions may demonstrate enhancement with gadolinium, often in an open ring (as compared to the complete ring of contrast enhancement seen with tumor and abscess)
  • The damage caused by lesions over time can lead to T1 hypointensities at sites of prior demyelination (T1 black holes).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Visual Evoked Potentials

A
  • Examine a particular EEG of visual stimulation (P100) to evaluate conduction along the visual pathway.
  • If the latency of P100 between the two eyes is significantly different, this suggests slowed conduction in one optic nerve, a sign of optic nerve dysfunction
  • In cases of possible MS, abnormal VEPs can suggest prior optic neuritis.
  • The optic nerve can also be examined by optical CT to look for prior damage to the nerve.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Pupillary reflex pathway

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

In order to diagnose MS, you need . . .

A

. . . multiple lesions that are separated by BOTH time AND space

In other words, many different lesions all at once is NOT MS, and repeated episodes of unifocal myelitis at one spot is NOT MS.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Optic neuritis

A
  • Painful loss of visual acuity in one eye
  • Common presenting symptom of MS, but may be due to a number of different myelopathies
  • Features:
    • Loss of visual acuity
    • Red desaturation
    • RAPD
    • Optic disc pallor or atrophy on exam
    • Pulling or tugging pain with EOMI
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Transverse myelitis

A
  • Inflammatory demyelination of the spinal cord
  • Reflexes may be exaggerated below the level of the lesion
  • Babinski signs may be present
  • Patients may report a “band of tingling or pain” around the torso at the level of the lesion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Internuclear ophthalmoplegia

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Five major features that suggest MS

A
  • Optic neuritis
  • Transverse myelitis
  • Internuclear ophthalmoplegia
  • Lhermitte’s sign
  • Uhthoff’s phenomenon
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Four different phenotypes of multiple sclerosis natural history

A
  • Relapsing-remitting (no baseline symptoms between episodes)
  • Progressive relapsing MS (starts as progressive symptoms, then with superimposed relapsing MS. Never remitting)
  • Secondary progressive phase (starts as relapsing remitting, then progresses with or without further superimposed relapses)
  • Primary progressive multiple sclerosis (no episodic exacerbations, just baseline change)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

LP for MS diangosis

A

Oligoclonal bands are the classic finding

Reflect the intrahectal production of IgG by plasma cell clones within the CNS

Nonspecific and can be seen in CNS infections and other CNS inflammatory conditions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Fingolimod

A

Mixed agonist-antagonist of the S1P Receptor

Downregulates S1P receptor within the lymphatic system, preventing T cells from following the chemotactic gradient and egressing. In effect, fingolimod decreases the cycle frequency of T cells and increases the lymphatic T cell storage at any given moment.

Bradycardia and macular edema are sometimes seen. Baseline electrocardiogram (ECG) and cardiac monitoring are required with the first dose. Baseline ophthalmologic examination and subsequent periodic ophthalmologic monitoring are also necessary.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Alemtuzumab

A
  • Anti-CD52 monoclonal antibody
  • Indicated for patients with relapsing forms of MS who have failed at least two other MS medications
  • Both T cells and B cells express CD52, however CD34+ HSCs do not
23
Q

Ocrelizumab

A

A different anti-CD20 monoclonal antibody

Indicated for relapsing-remitting and primary progressive MS

Contraindicated in patients with active hepatitis B

24
Q

Acute disseminated encephalomyelitis

A
  • Monophasic myelopathy leading to large areas of demyelination within the CNS
  • Commonly follows an immune response (viral infection, vaccination)
  • Presentation is similar to MS, but lesions are NOT distributed in time
  • Features that may be seen in ADEM:
    • MS phenomena, behavioral and cognitive abnormalities, seizures
  • Dx: Suspected based on clinical presentation and radiologic findings. LP shows lymphocytic pleocytosis and elevated protein
25
Q

Facial myokymia

A
  • Rare form of involuntary movement affecting the facial muscles
  • Clinically defined as continuous twitching of small bands or strips of muscles that give an undulating or rippling appearance to overlying skin
  • Descriptively called as `bag of worms’ appearance.
  • May be a presenting symptom of MS
  • https://www.youtube.com/watch?v=KaM3-qy8uqU
26
Q

Trigeminal neuralgia in MS

A

Very brief, but severe, lancinating maxillary or mandibular pain

Occurs in 1% of MS patients

May have multiple etiologies, but when this occurs in a young patient MS should be high on the differential

27
Q

Charcot’s triad

A
  • Well-recognized syndrome of MS, but occurs rarely
  • Triad of:
    1. Intention tremor
    2. Dysarthria
    3. Nystagmus
28
Q

Bladder symptoms in MS

A
  • Very common in MS patients
  • Most often involves overactive bladder
  • However, underactive bladder may also occur, and spinal cord lesions may also cause acute urinary retention
29
Q

Patients with MS have a high incidence of ___

A

Patients with MS have a high incidence of migraine headache

30
Q

Oligoclonal bands may be seen in. . .

A
  • MS
  • SLE
  • Neurosarcoidosis
  • Subacute sclerosing panencephalitis (SSPE)
  • Subarachnoid hemorrhage
  • Syphilis
  • CNS lymphoma
31
Q

CSF WBC count suggestive of MS

A

4-50 WBC

4-10 is the typical range

Anything more than 50 and you have something more inflammatory than MS

32
Q

Studies to rule out MS mimics

A
  • Laboratory studies
    • B12 level
  • Serologies
    • Lyme
    • Syphilis
    • Antiphospholipid antibodies
  • Inflammatory markes
    • ESR
    • CRP
    • ANA
33
Q

“Clinically isolated syndrome”

A

First demyelinating event that is suggestive of MS, but diagnosis of MS cannot be made due to lack of evidence of events separated by time and space

Most often in the setting of INO, 6th nerve palsy, cerebellar symptoms, partial transverse myelitis, or optic neuritis

34
Q

“Radiologically isolated syndrome”

A

Also called “preclinical MS”

Radiologic evidence of demyelinating disease is seen on imaging, but the patient reports no associated clinical symptoms

One in three of these patients will experience an attack leading to a diagnosis of MS within 5 years.

35
Q

Treatment of MS

A
  • Acute management:
    • IV seteroids for 5 days
    • Not disease modifying, but hastens time to recovery from a flare
  • Maintenance therapy:
    • Should be started as soon as the diagnosis of MS is made, since future events in MS can lead to permanent neurologic damage
    • Fingolimod (oral)
    • Teriflunomide (oral)
    • Dimethyl fumarate (oral)
    • Glatiramer acetate
    • Natalizumab (JCV titer)
    • Ocrelizumab (PPMS drug of choice)
    • Mixoxantrone (second-line due to cardiotoxicity)
    • Alemtuzumab (must have failed two other agents)
    • Interferon (not used anymore)
36
Q

Teriflunomide

A
  • Oral therapy for MS
  • Pyrimidine synthesis inhibitor, decreases T and B cell proliferation
  • Pregnancy class X AND men must use birth control as well as levels may be detected in the semen
37
Q

Dimethyl fumarate

A
  • Oral therapy for MS, but twice-daily
  • Promotes anti-inflammatory and cytoprotective activity by activating the Nrf2 antioxidant response pathway
  • Frequently associated with flushing and GI upset
38
Q

Only medication shown to be disease-modifying in patients with primary progressive MS

A

Ocrelizumab

an anti-CD20 monoclonal antibody

39
Q

Treating spasticity in MS

A

Baclofen, tizanidine

Both muscle relaxants

40
Q

Therapy for fatigue in MS

A

Amantadine (pro-dopaminergic, also Influenza A antiviral)

Modafinil (amphetamine stimulant, also used for narcolepsy)

Dalfampridine (K channel blocker, enhances conduction in damanged nerves)

41
Q

Dalfampridine

A

K channel blocker

Enhances conduction in damaged nerves

May be useful for some patients with MS and significant atrophy. Can improve walking and fatigue in patients experiencing these symptoms.

42
Q

Neurodegeneration in MS

A

Seen in the progressive forms of MS. When progressive patients have new symptoms, MRI usually will not show any abnormality other than atrophy.

This is because there is not a strong active inflammatory response. Rather, neurodegeneration is driving these symptoms.

43
Q

Glatiramer acetate

A

Polypeptide formulation injected subcutaneously in progressive and relapsing-remitting MS

It is a structural mimic of myelin basic protein that is given in a ‘desensitization’ fashion in order to skew the Th response away from a Th1 phenotype and towards a Th2 and Treg phenotype.

44
Q

In ADEM as opposed to MS, lesions are typically. . .

A

. . . multiple, more patchy, bilateral, and confluent

45
Q

Neuromyelitis optica

A
  • Characterized by the development of transverse myelitis and optic neuritis
    • These may develop simultaneously or separately
    • Demyelination in the brain should be absent or minor
  • In comparison to MS:
    • Pain is a more prominent feature
    • Focal deficits tend to be more severe
    • CSF pleocytosis (sometimes neutrophilic) is seen with greater frequency
  • Diagnosis: Presence of anti-AQP4 antibodies (aka NMO Ab) OR of anti-myelin oligodendrocyte glycoprotein (anti-MOG) Abs.
  • Treatment:
    • Acute: IV steroids, sometimes plasmapheresis
    • Maintenance: Azathioprine, mycophenolate mofetil, rituximab
46
Q

Progressive Multifocal Leukoencephalopathy

A
  • Characterized by dementia, focal cortical dysfunction, severe cerebellar abnormalities
  • Seen in a very select group of patients: AIDS+, leukemic, lymphomic, the otherwise severely immunocompromised, and those on natalizumab therapy
  • John Cunningham virus is the causative agent
  • Pathology: Demyelination due to infection of oligodrndrocytes
  • Diagnosis:
    • MRI shows multiple foci of white matter abnormalities, especially in the posterior regions of the brain.
    • CSF analysis is usually normal
  • Treatment:
    • There is no treatment other than supportive care
47
Q

Posterior reversible encephalopathy syndrome (PRES)

A
  • Leukoencephalopathy that develops in the context of rapidly developing hypertension, eclampsia, or due to calcineurin inhibitors
    • Tacrolimus, cyclosporine A
  • Characterized by acute confusional state and cortical visual loss (blindness with preserved pupillary reflexes)
  • Diagnosis: MRI showing posterior white matter hyperintensities
  • Treatment: May be reversible by treating the underlying condition, but not always. Calcium channel blockers may be effective.
48
Q

Adrenoleukodystrophy

A
  • Presentation: Addison’s disease plus diffuse myelopathy in a young child
  • X-linked mutation in ABCD1, which codes for a peroxisomal ATP-binding cassette transporter protein

Neurology Clerkship (60 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions